Market revenue in 2022 | USD 232.0 million |
Market revenue in 2030 | USD 319.9 million |
Growth rate | 4.1% (CAGR from 2022 to 2030) |
Largest segment | Viscosupplements |
Fastest growing segment | Synthetic |
Historical data | 2016 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Allografts, Synthetic, Cell-based, Viscosupplements |
Key market players worldwide | Anika Therapeutics Inc, Vericel Corp, Baxter International Inc, Zimmer Biomet Holdings Inc, Stryker Corp, Smith & Nephew PLC, BioTissue, MiMedx Group Inc, Arthrex, AlloSource, VSY Biotechnology, Aptissen |
Key Regions: Brazil , U.S. , Japan , South Africa , Saudi Arabia
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to orthopedic regenerative surgical products market will help companies and investors design strategic landscapes.
Viscosupplements was the largest segment with a revenue share of 41.38% in 2022. Horizon Databook has segmented the UK orthopedic regenerative surgical products market based on allografts, synthetic, cell-based, viscosupplements covering the revenue growth of each sub-segment from 2016 to 2030.
Major factors contributing to market growth are growing prevalence of orthopedic disorders and rising geriatric population in the country. Around 20.3 million individuals have a musculoskeletal condition, for example, arthritis or back pain, in the country, which is nearly one-third (32%) of the population.
Moreover, key strategic initiatives, such as mergers & acquisitions, by market players in the country further promote market growth. For instance, in January 2021, Smith & Nephew acquired Extremity Orthopaedics business from Integra LifeSciences Holdings Corporation for USD 240 million.
In 2020, Tissue Regenix Group introduced a new soft tissue orthopedic product under a white label distribution agreement. Tissue Regenix Group also targeted the UK as the first market for OrthoPure, which is a decellularized porcine tendon for the reconstruction of knee ligaments. Hence, such initiatives contribute to the country’s market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the UK orthopedic regenerative surgical products market , including forecasts for subscribers. This country databook contains high-level insights into UK orthopedic regenerative surgical products market from 2016 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account